Corteva, Inc. Form 8-K Summary
Business context and reporting period
Corteva filed a Current Report on Form 8-K under Item 5.02 on October 25, 2021, with the report signed October 28, 2021. The filing reports a planned chief executive officer transition and related executive compensation arrangements; it does not present quarterly or annual operating results for a financial reporting period.
- Charles Victor “Chuck” Magro will succeed James C. Collins, Jr. as CEO and join Corteva’s board effective November 1, 2021.
- Mr. Collins’ previously announced retirement as CEO and director will occur upon appointment of his successor.
- Mr. Magro will serve as a director until Corteva’s next annual meeting of stockholders.
- Mr. Magro previously served as president and CEO of Nutrien Ltd. from January 2018 through April 2021 and held senior leadership roles at Agrium Inc. and NOVA Chemicals.
Financial metrics and material compensation terms
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
- Annual base salary: $1.3 million.
- 2021 annual incentive opportunity: 150% of base salary, prorated based on the hire date.
- Target annual long-term incentive grant value beginning in 2022: $9.0 million, subject to the 2019 Corteva Omnibus Incentive Plan.
- Relocation and moving expenses: up to $750,000 in aggregate.
- CEO stock ownership guideline: six times base salary.
- Corteva agreed to pay Nutrien a lump sum of $18.7 million to coordinate Mr. Magro’s existing restrictive covenants.
- Corteva also agreed to indemnify Nutrien for specified breaches of those covenants and to comply with certain restrictive covenants generally expiring in 2023.
Changes, outlook, risks, and unusual items
The principal material change is the CEO succession from Mr. Collins to Mr. Magro, effective November 1, 2021. The appointment creates new executive compensation obligations and an immediate $18.7 million payment obligation to Nutrien.
The filing provides no financial guidance or quantitative business outlook. It identifies CEO transition risk among the factors that could affect future results and includes customary forward-looking statement cautions.
Other disclosed risks include regulatory approval and product-development risks, biotechnology acceptance, competition and generic products, environmental compliance, climate and weather, commodity and input-cost volatility, supply-chain and information-technology disruptions, dependence on third parties, capital-market access, customer credit, pension obligations, litigation and indemnification liabilities, global operations, acquisitions and divestitures, COVID-19, activist stockholders, intellectual property, counterfeit products, separation-related matters, the Biden administration’s competition initiative, and other risks described in Corteva’s periodic filings.
Important facts for investors to verify
- Confirm the effective date and completion of Mr. Magro’s CEO and board appointments.
- Review the full October 25, 2021 letter agreement and Change in Control and Executive Severance Plan filed as Exhibits 10.1 and 10.2.
- Assess the cash and accounting treatment of the $18.7 million payment to Nutrien and any related indemnification exposure.
- Review the terms and eventual value of the 2021 prorated incentive and future $9.0 million target long-term incentive awards.
- Monitor whether the CEO transition affects Corteva’s strategy, operating performance, capital allocation, or future guidance.
- Review subsequent filings for additional compensation, severance, restrictive-covenant, litigation, or transition-related disclosures.